PDGFRB and neoplasm: Despite encouraging clinical results for CML, and for GIST7, imatinib has failed clinical trials for glioblastoma, where it shows no significant inhibition of tumour growth or extension of survival8, 9 Imatinib and nilotinib potently inhibit tyrosine kinases including ARG, c-KIT, PDGFR and DDR1.